[The effect of CTLA4Ig-modified dendritic cells on proliferation and cytotoxicity of lymphocytes in-vitro].
OBJECTIVE
To study the effect of dendritic cells (DCs) modified by CTLA4Ig on T-cell proliferation and the cytotoxic T lymphocyte killer activity.


METHODS
The expressing vector pG/CTLA4Ig was transfected into DCs via lipofectamine reagent mediation. CTLA4Ig fusion protein secreted by DCs in the culture supernatant was confirmed by sandwich ELISA and SDS-PAGE. Peripheral blood mononuclear cells (PBMC) from C57BL/6 mice (as reaction cells) and DCs modified or unmodified by CTLA4Ig (as stimulation cells) were co-cultured for 6 days. MTT colorimetry was used to detect lymphocyte proliferation. Lactate dehydrogenase release method and sandwich ELISA assay was used to examine the cytotoxic activity and T-cell apoptosis.


RESULTS
CTLA4Ig fusion protein and DCs modified by CTLA4Ig could significantly inhibit lymphocyte proliferation response and cytotoxic activity of specific cytotoxic T lymphocytes, and induce T-cell apoptosis, while unmodified-DCs could markedly induce lymphocyte proliferation response.


CONCLUSIONS
The DCs of stably expressing CTLA4Ig fusion protein could not only markedly inhibit T-cell proliferation and cytotoxic activity of CTL, but also induce T-cell apoptosis.
Qiu
Wen-hong
WH
Department of Immunology, Tongji Medical College,Huazhong University of Science and Technology, Wuhan 430030, China.
Guo
Kai-wen
KW
Zhang
Yue
Y
Yang
Jin
J
Wang
Guo-hua
GH
Liao
Wen-jun
WJ
Shen
Guan-xin
GX
D000069594:Abatacept; D000818:Animals; D017209:Apoptosis; D003602:Cytotoxicity, Immunologic; D003713:Dendritic Cells / Q000502:physiology*; D018796:Immunoconjugates / Q000494:pharmacology*; D008213:Lymphocyte Activation; D007959:Lymphocyte Culture Test, Mixed; D051379:Mice; D008810:Mice, Inbred C57BL; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014162:Transfection
D018796:Immunoconjugates; D000069594:Abatacept